NASDAQ:CALA
$0.360
(
1.69%
)
Friday, 2nd Jun 2023
Calithera Biosciences Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $0.0100 | $0.370 | Friday, 2nd Jun 2023 CALA stock ended at $0.360. This is 1.69% more than the trading day before Thursday, 1st Jun 2023. During the day the stock fluctuated 2.82% from a day low at $0.355 to a day high of $0.365. |
| 90 days | $0.0100 | $0.370 | |
| 52 weeks | $0.0100 | $5.10 |
Historical Calithera Biosciences prices
| Date | Open | High | Low | Close | Volume |
| 2023-06-02 | $0.355 | $0.365 | $0.355 | $0.360 | 30 157 |
| 2023-06-01 | $0.354 | $0.354 | $0.354 | $0.354 | 8 756 |
| 2023-05-31 | $0.348 | $0.360 | $0.340 | $0.360 | 24 473 |
| 2023-05-30 | $0.350 | $0.350 | $0.350 | $0.350 | 5 630 |
| 2023-05-26 | $0.370 | $0.370 | $0.355 | $0.355 | 17 524 |
| 2023-05-25 | $0.335 | $0.365 | $0.335 | $0.365 | 47 643 |
| 2023-05-24 | $0.320 | $0.365 | $0.315 | $0.350 | 120 707 |
| 2023-05-23 | $0.310 | $0.335 | $0.300 | $0.330 | 131 886 |
| 2023-05-22 | $0.0700 | $0.340 | $0.0500 | $0.311 | 887 119 |
| 2023-05-19 | $0.0300 | $0.0300 | $0.0300 | $0.0300 | 0 |
| 2023-05-18 | $0.0400 | $0.0500 | $0.0300 | $0.0300 | 2 724 |
| 2023-05-17 | $0.0260 | $0.0260 | $0.0260 | $0.0260 | 579 |
| 2023-05-16 | $0.0829 | $0.0829 | $0.0250 | $0.0250 | 2 231 |
| 2023-05-15 | $0.0251 | $0.0310 | $0.0250 | $0.0250 | 904 |
| 2023-05-12 | $0.0360 | $0.0360 | $0.0261 | $0.0261 | 16 398 |
| 2023-05-11 | $0.0300 | $0.0400 | $0.0300 | $0.0300 | 1 262 |
| 2023-05-10 | $0.0400 | $0.0400 | $0.0270 | $0.0270 | 2 409 |
| 2023-05-09 | $0.0250 | $0.0929 | $0.0250 | $0.0400 | 13 284 |
| 2023-05-08 | $0.0250 | $0.0439 | $0.0250 | $0.0439 | 105 032 |
| 2023-05-05 | $0.0399 | $0.0399 | $0.0250 | $0.0250 | 5 391 |
| 2023-05-04 | $0.0100 | $0.0325 | $0.0100 | $0.0250 | 11 035 |
| 2023-05-03 | $0.0250 | $0.0325 | $0.0250 | $0.0250 | 17 942 |
| 2023-05-02 | $0.0250 | $0.0290 | $0.0250 | $0.0250 | 5 616 |
| 2023-05-01 | $0.0150 | $0.0369 | $0.0150 | $0.0250 | 28 041 |
| 2023-04-28 | $0.0100 | $0.0450 | $0.0100 | $0.0200 | 140 906 |
| 2023-04-27 | $0.0400 | $0.0520 | $0.0400 | $0.0400 | 23 730 |
| 2023-04-26 | $0.0410 | $0.0580 | $0.0410 | $0.0422 | 12 974 |
| 2023-04-25 | $0.0400 | $0.0580 | $0.0400 | $0.0400 | 5 869 |
| 2023-04-24 | $0.0450 | $0.0450 | $0.0400 | $0.0400 | 8 450 |
| 2023-04-21 | $0.0400 | $0.0400 | $0.0400 | $0.0400 | 1 376 |
| 2023-04-20 | $0.0410 | $0.0550 | $0.0410 | $0.0410 | 20 539 |
| 2023-04-19 | $0.0400 | $0.0569 | $0.0400 | $0.0410 | 567 |
| 2023-04-18 | $0.0411 | $0.0520 | $0.0411 | $0.0520 | 92 339 |
| 2023-04-17 | $0.0411 | $0.0700 | $0.0411 | $0.0422 | 2 866 |
| 2023-04-14 | $0.0600 | $0.0600 | $0.0410 | $0.0560 | 4 711 |
| 2023-04-13 | $0.0400 | $0.0560 | $0.0400 | $0.0560 | 1 748 |
| 2023-04-12 | $0.0700 | $0.0718 | $0.0411 | $0.0420 | 5 835 |
| 2023-04-11 | $0.0400 | $0.0770 | $0.0400 | $0.0460 | 8 910 |
| 2023-04-10 | $0.0450 | $0.0799 | $0.0420 | $0.0520 | 72 322 |
| 2023-04-06 | $0.0450 | $0.0500 | $0.0450 | $0.0500 | 514 |
| 2023-04-05 | $0.0500 | $0.0525 | $0.0465 | $0.0525 | 746 |
| 2023-04-04 | $0.0580 | $0.0600 | $0.0425 | $0.0470 | 7 719 |
| 2023-04-03 | $0.0450 | $0.103 | $0.0410 | $0.0590 | 57 859 |
| 2023-03-31 | $0.0450 | $0.0550 | $0.0400 | $0.0550 | 66 403 |
| 2023-03-30 | $0.0550 | $0.0550 | $0.0401 | $0.0401 | 25 619 |
| 2023-03-29 | $0.0400 | $0.0550 | $0.0400 | $0.0550 | 60 546 |
| 2023-03-28 | $0.0410 | $0.0440 | $0.0400 | $0.0400 | 32 348 |
| 2023-03-27 | $0.0410 | $0.0500 | $0.0410 | $0.0500 | 8 673 |
| 2023-03-24 | $0.0450 | $0.0500 | $0.0410 | $0.0442 | 2 848 |
| 2023-03-23 | $0.0450 | $0.0450 | $0.0450 | $0.0450 | 261 |
About Calithera Biosciences
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
